Adagrasib, another potent, covalent KRAS inhibitor that selectively binds KRASG12C, demonstrated encouraging clinical activity in the phase I/II KRYSTAL-1 trial (NCT03785249); in pretreated NSCLC patients with KRASG12C mutations, the ORR was 45% [9]. Here, KRAS is linked to non-small cell lung carcinoma.